Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase lb, Five Period Crossover, Open-Label Study Evaluating a Single Dose Administration of 3mL or 5mL of Inhaled AeroLEF (Liposome-Encapsulated Fentanyl 500 Mcg/mL), Delivered by up to Four Aerosol Delivery Devices in Healthy Subjects

NCT00794209 is registered in ClinicalTrials.gov with YM BioSciences as lead sponsor.

NCT NCT00794209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00794209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase lb, Five Period Crossover, Open-Label Study Evaluating a Single Dose Administration of 3mL or 5mL of Inhaled AeroLEF (Liposome-Encapsulated Fentanyl 500 Mcg/mL), Delivered by up to Four Aerosol Delivery Devices in Healthy Subjects
Lead sponsor
YM BioSciences
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2003
Completion date
May 31, 2003
Enrollment
9 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy